TP53-mutated AML: No survival benefit with addition of venetoclax to standard therapies

Key clinical point: The addition of venetoclax to standard treatment regimens (VEN-based) did not improve clinical outcomes in patients with TP53-mutated acute myeloid leukemia (AML), highlighting the need for novel therapies in this patient population.

Major finding: Overall, no significant differences were observed in the rates of composite complete remission (P = .18), overall survival (median, 5.7 months vs 6.6 months; P = .4), relapse-free survival (median, 3.5 months vs 4.7 months; P = .43), 4-week mortality (7% vs 10%; P = .5), and 8-week mortality (22% vs 17%; P = .4) in patients receiving VEN-based vs non-VEN-based therapies.

Study details: Findings are from a retrospective analysis of 238 patients with newly diagnosed TP53-mutated AML treated with either VEN-based (n=58) or non-VEN-based (n=180) therapies.

Disclosures: This study was supported partly by the University of Texas MD Anderson Cancer Center Support Grant from the National Cancer Institute. Some investigators reported ties with various pharmaceutical companies.

Source: Venugopal S et al. Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.

Key clinical point: The addition of venetoclax to standard treatment regimens (VEN-based) did not improve clinical outcomes in patients with TP53-mutated acute myeloid leukemia (AML), highlighting the need for novel therapies in this patient population.

Major finding: Overall, no significant differences were observed in the rates of composite complete remission (P = .18), overall survival (median, 5.7 months vs 6.6 months; P = .4), relapse-free survival (median, 3.5 months vs 4.7 months; P = .43), 4-week mortality (7% vs 10%; P = .5), and 8-week mortality (22% vs 17%; P = .4) in patients receiving VEN-based vs non-VEN-based therapies.

Study details: Findings are from a retrospective analysis of 238 patients with newly diagnosed TP53-mutated AML treated with either VEN-based (n=58) or non-VEN-based (n=180) therapies.

Disclosures: This study was supported partly by the University of Texas MD Anderson Cancer Center Support Grant from the National Cancer Institute. Some investigators reported ties with various pharmaceutical companies.

Source: Venugopal S et al. Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.

Key clinical point: The addition of venetoclax to standard treatment regimens (VEN-based) did not improve clinical outcomes in patients with TP53-mutated acute myeloid leukemia (AML), highlighting the need for novel therapies in this patient population.

Major finding: Overall, no significant differences were observed in the rates of composite complete remission (P = .18), overall survival (median, 5.7 months vs 6.6 months; P = .4), relapse-free survival (median, 3.5 months vs 4.7 months; P = .43), 4-week mortality (7% vs 10%; P = .5), and 8-week mortality (22% vs 17%; P = .4) in patients receiving VEN-based vs non-VEN-based therapies.

Study details: Findings are from a retrospective analysis of 238 patients with newly diagnosed TP53-mutated AML treated with either VEN-based (n=58) or non-VEN-based (n=180) therapies.

Disclosures: This study was supported partly by the University of Texas MD Anderson Cancer Center Support Grant from the National Cancer Institute. Some investigators reported ties with various pharmaceutical companies.

Source: Venugopal S et al. Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.